DNA Nanobots

DNA Nanobots is a private, pre-clinical stage biotech leveraging DNA origami nanotechnology to create targeted delivery systems for therapeutics. Its core platform uses programmable DNA nanostructures as 'nanobots' to deliver chemotherapy, gene therapies, and vaccines directly to specific cells, aiming to improve efficacy and reduce off-target toxicity. The company pursues a dual business model, developing its own internal pipeline while offering design and development services to pharmaceutical partners. Based in Cambridge, USA, it was founded in 2018 (spun out in 2021) based on foundational IP from Professor Carlos E. Castro's lab.

Programmable DNA origami nanoparticle platform for the targeted delivery of therapeutic payloads (chemo drugs, genes, vaccine antigens). Enables design of custom nanoscale structures with precise functionalization for cell-specific targeting and triggered release.

Competes in the broad targeted drug delivery space against companies using lipid nanoparticles (e.g., Moderna, BioNTech), viral vectors, antibody-drug conjugates (ADCs), and other nanomedicine approaches (e.g., polymer nanoparticles). Differentiation hinges on proving superior precision, safety, and programmability of its DNA origami platform.